2 completed, 1 not yet recruiting. 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Maraviroc (MVC): new trials by email Literature Review of Maraviroc (MVC) trials Research Report on Maraviroc (MVC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc - Long COVID | Phase 2 / Phase 3 | Not yet recruiting | HealthBio, Inc. | 252 | 2026-07-15 | 2026-06-18 |
| Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND) Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG) - HIV Infections | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 191 | 2016-04-21 | 2022-04-22 |
| IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults Raltegravir (RAL), Atazanavir (ATV), Ritonavir (RTV) - HIV Infections | Completed | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 168 | 2002-08-01 | 2015-08-07 |
HIV Infections (2) · Post-Acute COVID-19 Syndrome (1)
HealthBio, Inc. (1) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3) · Puerto Rico (2) · Brazil (1) · South Africa (1) · Thailand (1)
Jennifer R. King, PharmD (1) · Kevin Robertson, PhD (1) · Ram Yogev, MD (1)
U01AI068632 (1)